Aptose Biosciences (APTO) Expected to Announce Earnings on Tuesday

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) is expected to post its quarterly earnings results before the market opens on Tuesday, March 25th. Analysts expect Aptose Biosciences to post earnings of ($1.21) per share for the quarter.

Aptose Biosciences Trading Down 6.1 %

APTO opened at $3.69 on Friday. The stock has a market cap of $7.90 million, a PE ratio of -1.24 and a beta of 1.14. Aptose Biosciences has a 1 year low of $2.39 and a 1 year high of $51.61. The stock’s 50 day simple moving average is $4.84 and its 200-day simple moving average is $7.78.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on APTO shares. Alliance Global Partners upgraded Aptose Biosciences to a “strong-buy” rating in a research report on Thursday, February 27th. HC Wainwright reiterated a “buy” rating and issued a $60.00 price target on shares of Aptose Biosciences in a research report on Wednesday, February 12th. Finally, StockNews.com started coverage on Aptose Biosciences in a research report on Wednesday, March 5th. They issued a “sell” rating on the stock. One equities research analyst has rated the stock with a sell rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $130.00.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.